Comparative effectiveness of antibiotic treatment strategies for pediatric skin and soft-tissue infections
- PMID: 21844058
- PMCID: PMC3387880
- DOI: 10.1542/peds.2010-3681
Comparative effectiveness of antibiotic treatment strategies for pediatric skin and soft-tissue infections
Abstract
Objective: To compare the effectiveness of clindamycin, trimethoprim-sulfamethoxazole, and β-lactams for the treatment of pediatric skin and soft-tissue infections (SSTIs).
Methods: A retrospective cohort of children 0 to 17 years of age who were enrolled in Tennessee Medicaid, experienced an incident SSTI between 2004 and 2007, and received treatment with clindamycin (reference), trimethoprim-sulfamethoxazole, or a β-lactam was created. Outcomes included treatment failure and recurrence, defined as an SSTI within 14 days and between 15 and 365 days after the incident SSTI, respectively. Adjusted models stratified according to drainage status were used to estimate the risk of treatment failure and time to recurrence.
Results: Among the 6407 children who underwent drainage, there were 568 treatment failures (8.9%) and 994 recurrences (22.8%). The adjusted odds ratios for treatment failure were 1.92 (95% confidence interval [CI]: 1.49-2.47) for trimethoprim-sulfamethoxazole and 2.23 (95% CI: 1.71-2.90) for β-lactams. The adjusted hazard ratios for recurrence were 1.26 (95% CI: 1.06-1.49) for trimethoprim-sulfamethoxazole and 1.42 (95% CI: 1.19-1.69) for β-lactams. Among the 41 094 children without a drainage procedure, there were 2435 treatment failures (5.9%) and 5436 recurrences (18.2%). The adjusted odds ratios for treatment failure were 1.67 (95% CI: 1.44-1.95) for trimethoprim-sulfamethoxazole and 1.22 (95% CI: 1.06-1.41) for β-lactams; the adjusted hazard ratios for recurrence were 1.30 (95% CI: 1.18-1.44) for trimethoprim-sulfamethoxazole and 1.08 (95% CI: 0.99-1.18) for β-lactams.
Conclusions: Compared with clindamycin, use of trimethoprim-sulfamethoxazole or β-lactams was associated with increased risks of treatment failure and recurrence. Associations were stronger for those with a drainage procedure.
Figures
Similar articles
-
Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus.Pediatrics. 2009 Jun;123(6):e959-66. doi: 10.1542/peds.2008-2428. Epub 2009 May 26. Pediatrics. 2009. PMID: 19470525
-
Trimethoprim-sulfamethoxazole or clindamycin for treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections.Pediatr Infect Dis J. 2009 Jan;28(1):57-9. doi: 10.1097/INF.0b013e3181826e5e. Pediatr Infect Dis J. 2009. PMID: 19057459
-
A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses.N Engl J Med. 2017 Jun 29;376(26):2545-2555. doi: 10.1056/NEJMoa1607033. N Engl J Med. 2017. PMID: 28657870 Free PMC article. Clinical Trial.
-
Antimicrobial agents for the dermatologist. II. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim-sulfamethoxazole, and clindamycin.J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):365-81; quiz 382-4. doi: 10.1016/s0190-9622(97)70135-x. J Am Acad Dermatol. 1997. PMID: 9308549 Review.
-
The use of trimethoprim and sulfamethoxazole (TMP-SMX) in dermatology.Folia Med Cracov. 2015;55(1):35-41. Folia Med Cracov. 2015. PMID: 26774630 Review.
Cited by
-
''Myth Busting in Infectious Diseases'': A Comprehensive Review.Cureus. 2024 Mar 30;16(3):e57238. doi: 10.7759/cureus.57238. eCollection 2024 Mar. Cureus. 2024. PMID: 38686221 Free PMC article. Review.
-
Antibiotic susceptibility and clonal distribution of Staphylococcus aureus from pediatric skin and soft tissue infections: 10-year trends in multicenter investigation in China.Front Cell Infect Microbiol. 2023 Jul 13;13:1179509. doi: 10.3389/fcimb.2023.1179509. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37520432 Free PMC article.
-
Variation in Antibiotic Treatment Failure Outcome Definitions in Randomised Trials and Observational Studies of Antibiotic Prescribing Strategies: A Systematic Review and Narrative Synthesis.Antibiotics (Basel). 2022 May 6;11(5):627. doi: 10.3390/antibiotics11050627. Antibiotics (Basel). 2022. PMID: 35625271 Free PMC article. Review.
-
Is Trimethoprim-Sulfamethoxazole a Valid Alternative in the Management of Infections in Children in the Era of Community-Acquired Methicillin-Resistant Staphylococcus aureus? A Comprehensive Systematic Review.J Pharm Technol. 2016 Apr;32(2):81-87. doi: 10.1177/8755122515622484. Epub 2016 Jan 21. J Pharm Technol. 2016. PMID: 34860972 Free PMC article. Review.
-
IBT-V02: A Multicomponent Toxoid Vaccine Protects Against Primary and Secondary Skin Infections Caused by Staphylococcus aureus.Front Immunol. 2021 Mar 10;12:624310. doi: 10.3389/fimmu.2021.624310. eCollection 2021. Front Immunol. 2021. PMID: 33777005 Free PMC article.
References
-
- Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med. 2008;168(14):1585–1591 - PubMed
-
- Buckingham SC, McDougal LK, Cathey LD, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus at a Memphis, Tennessee Children's Hospital. Pediatr Infect Dis J. 2004;23(7):619–624 - PubMed
-
- National Nosocomial Infections Surveillance System National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470–485 - PubMed
-
- Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis. 2005;40(12):1785–1791 - PubMed
-
- Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352(14):1436–1444 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
